EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacokinetic Interaction Between Pioglitazone and Clopidogrel in Rats Assessed by a Practice-Oriented LC-MS/MS Method for Clopidogrel Carboxylic Acid

Mohammad Majed Hailat, Wael Abu Dayyih, Sahar M. Al Nabulsi

Acta Poloniae Pharmaceutica - Drug Research · 03.08.2026 · 84 (2) · 259-268

DOI: 10.32383/appdr/225905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Poloniae Pharmaceutica - Drug Research, online erschienen am 03.08.2026. Verfasst von Mohammad Majed Hailat und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The carboxylic acid metabolite of clopidogrel (clopidogrel CA) is the principal circulating species formed after oral administration of the drug and is widely used as a surrogate marker for clopidogrel disposition. This work aimed to develop and validate a simple, rapid and practice-oriented liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for quantifying clopidogrel CA in rat plasma and to apply it to evaluate a potential pharmacokinetic interaction with the antidiabetic agent pioglitazone. Chromatographic separation was achieved on a C18 column using an isocratic mobile phase of acetonitrile and 0.001 M ammonium chloride (80:20, v/v) at a flow rate of 0.45 mL/min, with glimepiride as the internal standard. Detection was performed in positive-ion multiple reaction monitoring mode (m/z 308.1 → 113.2 for clopidogrel CA and 491.5 → 126.3 for glimepiride). The method was linear over the range 0.075–12.0 µg/mL and met the acceptance criteria of the FDA and EMA bioanalytical method validation guidelines for selectivity, linearity, precision, accuracy and recovery. Oral co-administration of pioglitazone (30 mg/kg) with clopidogrel (10 mg/kg) significantly reduced the mean peak plasma concentration (Cmax) of clopidogrel CA from 8.896 to 6.599 µg/mL (p < 0.05), produced a non-significant decrease in AUC0–24 (81.423 vs 73.818 µg·h/mL, p > 0.05) and delayed the time to peak concentration. These findings indicate a measurable pharmacokinetic interaction between pioglitazone and clopidogrel that warrants confirmation using active metabolite and pharmacodynamic endpoints.

Zitieren

APA

Hailat, M. M., Dayyih, W. A., & Nabulsi, S. M. A. (2026). Pharmacokinetic Interaction Between Pioglitazone and Clopidogrel in Rats Assessed by a Practice-Oriented LC-MS/MS Method for Clopidogrel Carboxylic Acid. Acta Poloniae Pharmaceutica - Drug Research, 84(2), 259-268. https://doi.org/10.32383/appdr/225905

Vancouver

Hailat MM, Dayyih WA, Nabulsi SMA. Pharmacokinetic Interaction Between Pioglitazone and Clopidogrel in Rats Assessed by a Practice-Oriented LC-MS/MS Method for Clopidogrel Carboxylic Acid. Acta Poloniae Pharmaceutica - Drug Research. 2026;84(2):259-268. doi:10.32383/appdr/225905

BibTeX
@article{Hailat2026,
  author = {Hailat, Mohammad Majed and Dayyih, Wael Abu and Nabulsi, Sahar M. Al},
  title = {Pharmacokinetic Interaction Between Pioglitazone and Clopidogrel in Rats Assessed by a Practice-Oriented LC-MS/MS Method for Clopidogrel Carboxylic Acid},
  journal = {Acta Poloniae Pharmaceutica - Drug Research},
  year = {2026},
  volume = {84},
  number = {2},
  pages = {259--268},
  doi = {10.32383/appdr/225905}
}
Kostenlos starten →